AstraZeneca
NEWS
The trial will enroll about 4,000 people worldwide to confirm the drug’s safety and immunogenicity profiles.
Scientists from the U.K. conducted a massive study on the link between vaccinations and dropping platelet counts and found that the problem lies more on the virus itself than on the medications.
The FoCus Phase III trial by Alexion and AstraZeneca showed that ALXN1840 demonstrated around three times greater copper mobilization from tissues than SoC treatments for Wilson disease.
It was another busy week in clinical trial news. Here’s a look.
The group said that the Phase III trial of Ultomiris (ravulizumab) lacked efficacy when it was used on adults diagnosed with amyotrophic lateral sclerosis.
There was plenty of clinical trial updates last week. Here’s a look.
In India, only 8.3% of the population is fully vaccinated, while Sudan, Myanmar, and Ethiopia all have blank spaces beside their names in that category.
The clinical study compared Enhertu to Kadcyla in HER2+ metastatic breast cancer patients who previously received trastuzumab.
Sierra will have access to AZD5153, a potent and selective BRD4 BET inhibitor, to initiate a study that combines the said component with momelotinib for treating patients with myelofibrosis.
JOBS
IN THE PRESS